Pfizer Inc.’s Paxlovid has become such a part of the COVID-19 treatment scene in the U.S. that it’s easy to forget it’s only authorized for emergency use. That could soon change. The FDA is convening its Antimicrobial Drugs Advisory Committee March 16 to consider Pfizer’s NDA for the co-packaged nirmatrelvir and ritonavir treatment.
Pardes Biosciences Inc. has patented 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of viral infections.
Exevir Bio BV has announced research detailing a novel, highly potent, anti-S2 camelid single-domain antibody, discovered at the VIB-Ugent Center for Medical Biotechnology, and developed as a candidate drug molecule by Exevir as XVR-013.
Researchers from Case Western Reserve University presented data from a study that aimed to investigate gut integrity, oxidized lipids and inflammatory markers associated with the pathogenesis of post-acute sequelae of COVID-19 (PASC).
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Antev, Biogen, Biomarin, Boehringer, Eli Lilly, Inhibikase, Mesoblast, Revive, Sage.
The FDA’s emergency use authorization (EUA) program for rapid antigen tests for the COVID-19 pandemic is coming to an end, but few rapid antigen test makers have laid out clear plans regarding the post-public health emergency world. Quidelortho Corp. managed to beat the competition to the non-EUA market for these tests with a grant of de novo petition for its Sofia rapid antigen test, which now provides other tests with a predicate device, thus ensuring that this will not be the last such test to reach the U.S. market.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Ab2, Dyadic, Enthera, Indaptus, Infectious Disease Research Institute, Janssen, Maia, Merck & Co., Panbela, Protagonist, Small.
The U.S. Recover program, set up in July 2022 to identify the causes of long COVID, find biomarkers of disease and discover new therapeutic targets, is now preparing to move to its next phase and begin testing potential treatments in a multi-arm, randomized, placebo-controlled trial. But with 200 different symptoms, and limited understanding of relevant system-level pathological targets, there are significant hurdles to be overcome.
RSS
